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Abstract Hereditary protein S (PS) deWciency is an auto-
somal disorder caused by mutations in the PS gene
(PROS1). Conventional PCR-based mutation detection
identiWes PROS1 point mutations in approximately 50% of
the cases. To verify if gross copy number variations
(CNVs) are often present in point mutation-negative here-
ditary PS deWciency we used multiplex ligation-dependent
probe ampliWcation (MLPA) as a detection tool in samples
from individuals with a high probability of having true PS
deWciency. To this end, DNA samples from nine PS deW-
cient probands with family members (seven type I and two
type III) and nine isolated probands (three type I and six
type III), in whom PROS1 mutations were not found by
DNA sequencing, were evaluated. An independent quanti-
tative PCR (qPCR) was performed to conWrm the Wndings
of the MLPA assay. Family members were also tested
when DNA was available. Gross abnormalities of PROS1
were found in six out of eighteen probands. In three pro-
bands complete deletion of the gene was detected. Two
probands had a partial deletion involving diVerent parts of
the gene (one from exon 4 through 9 and another from exon
9 through 11). One family showed a duplication of part of
PROS1. qPCR analysis was in accordance with these
results. In conclusion, this study substantiates that gross
gene abnormalities in PROS1 are relatively common in
hereditary PS deWcient patients and that MLPA is a useful
tool for direct screening of CNVs in PROS1 point muta-
tion-negative individuals.
Introduction
Protein S (PS; MIM 176880) is a vitamin K-dependent
plasma glycoprotein that functions as a non-enzymatic co-
factor of activated protein C (APC) in the proteolytic degra-
dation of activated factor V and activated factor VIII
(Dahlbäck 2000; Esmon 1987). Approximately 60% of PS
is non-covalently bound to C4b-binding protein (C4BP).
The remaining 40% circulates as free PS and represents the
biologically active portion of circulating PS (Dahlbäck and
StenXo 1981). It was demonstrated recently that the C4BP-
bound PS may play a role in the inactivation of activated
factor V (Maurissen et al. 2008).
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450 Hum Genet (2009) 126:449–456Inherited PS deWciency is considered to be an autosomal
haploinsuYciency disorder that is associated with venous
thrombosis. It is generally classiWed in three categories: (a)
type I, characterized by a quantitative deWciency of total
and free PS antigen; (b) type II, characterized by a qualita-
tive defect with reduced APC cofactor activity but normal
levels of total and free PS antigen; (c) type III, characterized
by a quantitative deWciency of free PS antigen only (Bertina
1990).
The precise prevalence of PS deWciency remains
unknown because it is quite rare and because a correct diag-
nosis with plasma assays is complicated. The latter is the
result of limitations of the laboratory techniques and of the
fact that PS levels are inXuenced by acquired and hereditary
factors, such as age, sex, pregnancy, oral contraceptive use,
vitamin K intake and polymorphisms in the PS gene (Pers-
son et al. 2003; Ten Kate and van der Meer 2008). In throm-
botic patients, the estimated prevalence of inherited PS
deWciency varies from 2–5% in unselected patients to
1–13% in selected patients from thrombophilia families (Lane
et al. 1996; Seligsohn and Lubetsky 2001; Ten Kate and van
der Meer 2008), while in the general population estimates
diVer sharply between 0.03 and 0.13% (Dykes et al. 2001).
PS is encoded by PROS1 which is approximately 80 kb
long and consists of 15 exons and 14 introns. PROS1 is
located near the centromere of chromosome 3 at position
3q11.2 (Schmidel et al. 1990). A transcriptionally silent
pseudogene (PROSP) is located close to PROS1 and is 95
and 97% similar to PROS1 for introns and exons, respec-
tively, except for exon 1, which is absent in PROSP (Ploos
van Amstel et al. 1987, 1990). Both the large size of the
gene and the presence of the pseudogene complicate the
study of PROS1 mutations.
Screening for PROS1 mutations has been performed in a
number of studies (Espinosa-Parrilla et al. 1999; Gómez
et al. 1995; Johansson et al. 2005; Reitsma et al. 1994).
Many of these were based on a strategy of resequencing
exons and Xanking intronic regions. More than 200 diVer-
ent PROS1 mutations have been described up to now. The
vast majority of these are missense or nonsense mutations
and only a few are gross deletions or duplications (Gan-
drille et al. 2000; Stenson et al. 2009; Ten Kate and van der
Meer 2008). In type I and III PS deWciency, the mutations
are spread throughout PROS1, while type II is usually
caused by missense mutations in exons 5 and 8, which
encode the epidermal growth factor (EGF)-like domains
(García de Frutos et al. 2007). Coexistence of type I and III
deWciencies in the same family has been described and
seems to be explained by the observation that total PS lev-
els increase with age, whereas free PS levels are not inXu-
enced by age (Simmonds et al. 1997).
Overall, PROS1 mutations have been identiWed in only
50% of the PS deWcient families that were analyzed
(Johansson et al. 2005; Lanke et al. 2004). The reason for
this is poorly understood. Segregation of genetic markers in
PS deWcient families suggested that mutations should be
sought in or close to PROS1 (Lanke et al. 2004). Since
large deletions and duplications are not detected with a
PCR-based DNA sequencing approach, other techniques
were explored. Using segregation analysis, Johansson et al.
indirectly detected large deletions in several mutation-
negative patients with PS deWciency (Johansson et al.
2005). Furthermore, three case-reports have been published
that used a multiplex ligation-dependent probe ampliWca-
tion analysis (MLPA) which detected two large deletions
(Yin et al. 2007; Yoo et al. 2009) and one large duplication
(Choung et al. 2008) in patients with PS deWciency. MLPA
is a technique that allows the evaluation of multiple frag-
ments from a gene in a single reaction and can detect copy
number variation (CNV) involving one or more exons
(Schouten et al. 2002).
The aim of this study was to investigate whether large
deletions or duplications are common in hereditary PS deW-
ciency and whether MLPA represents a useful screening




DNA samples were obtained from families or isolated pro-
bands who were recruited by a French network which was
set up to study PS deWciency. The probands were consecu-
tive patients who were referred to a specialized clinical
hematology laboratory because they had at least one epi-
sode of thrombosis of unidentiWed cause. The clinical crite-
ria for including PS deWcient thrombotic patients
(probands) and the PCR-based DNA resequencing results
have been described before in three reports (Borgel et al.
1996; Duchemin et al. 1996; Gandrille et al. 1995). The
diagnosis of PS deWciency was based on a total PS level
below 65% of normal, as measured with an immunologic
assay (Asserachrom Protein S; Diagnostica Stago, Asniè-
res, France), and/or a free PS level below 65% of normal,
as measured with the same immunologic assay after preci-
pitation of the C4BP/PS complex with polyethylene glycol
(Comp et al. 1986). Sex, age, and pregnancy were not taken
into account when assigning a deWciency state. Patients
using vitamin K antagonists were excluded from analysis.
Patients who were classiWed as type I or type III PS deW-
cient were asked to provide blood for DNA analysis and a
second PS measurement. Only DNA from patients in whom
PS deWciency was conWrmed by a second assay was ana-
lyzed. Family studies were undertaken whenever possible.123
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network were selected with a high probability of having a
hereditary PS deWciency, either by having a family history
of PS deWciency transmission, or by having very low PS
measurements. In all of them, no mutation was found by
exon-targeted sequencing of PROS1. The panel (Table 1)
comprised eighteen probands out of which ten were type I
and eight were type III PS deWcient. Nine were isolated pro-
bands and nine were probands with thirty family members
including nine non-PS deWcient and twenty-one PS deW-
cient subjects. Families 1 and 2 (Gandrille et al. 1995)
(Borgel et al. 1996) and families 4 and 8 (Duchemin et al.
1996) were part of previous reports of the French network.
All other families and probands were not included in previ-
ous publications. PS measurements for the probands are
presented in Table 1.
MLPA
MLPA was performed as described before (Schouten et al.
2002) using the SALSA MLPA KIT P112 PROS1 (MRC-
Holland, Amsterdam, The Netherlands). BrieXy, MLPA is
a PCR-based technique for the relative quantiWcation of
genomic DNA sequences. The P112 PROS1 kit contains
thirteen probes that target twelve of the Wfteen exons of
PROS1, one probe targeting a segment of DNA which is
located 6.5 kb in front of the Wrst exon of PROS1, one
probe targeting exon 4 of the pseudogene (PROSP) and
twenty-one control probes targeting diVerent chromosomes
(chromosome 1, 2, 3, 5, 7, 9, 10, 12, 14, 15, 16, 18, 19, 21).
After ampliWcation, fragments were analyzed on an ABI
PRISM® 3730xl Analyzer (Applied Biosystems, Foster
City, CA, USA) and the GeneMapper software (Applied
Biosystems, Foster City, CA, USA) was used for visualiz-
ing peaks and calculating peak areas. Calculation of relative
probe signals was adapted from Schouten et al. (2002) and
obtained by dividing the peak area of a given exon probe by
the peak area of Xanking control probes. The results of test
samples were compared to the results of two diVerent pools
of control DNA samples that were run concurrently.
Deletions and duplications are apparent by a 35–50% varia-
tion of relative peak area of the ampliWcation product of a
given probe in comparison to the relative peak area of the
same probe for the control samples. When a deletion or
Table 1 Characteristics of probands with PS deWciency and MLPA results
a Normal PS level: ¸65%
b NM_000313.2, according to the guidelines of Mutation Nomenclature Homepage at the HGVS website (den Dunnen and Antonarakis 2000 at
http://www.hgvs.org/mutnomen accessed 12 May 2009)
c The involvement of exon 3 can not be ruled out as there is no probe for this exon in P112 MLPA kit
d The involvement of exon 8 can not be ruled out as there is no probe for this exon in P112 MLPA kit
e For this family, qPCR suggests that GPR15 is also deleted. Therefore, at least 5 Mb upstream from exon 1 of PROS1 are deleted








CNV in PROS1b Exons
PS deWcient Not PS deWcient
1 S1 1 0 45 40 Type I Not found –
2 S3 0 3 55 38 Type I c.(210_294)_(1323_1360)dup 4–11c
3 S11 0 0 55 23 Type I c.(697_909)_(1323_1360)del 9–11d
4 S17 1 0 63 22 Type I c.(?_-133)_(*1_?)del All
5 S20 1 1 55 42 Type I Not found –
6 S24 2 1 66 20 Type III Not found –
7 S27 5 0 19 37 Type I Not found –
8 S33 3 1 18 15 Type I c.(?_-133)_(*1_?)dele All
9 S38 0 0 84 31 Type III Not found –
10 S39 0 0 130 15 Type III Not found –
11 S40 0 0 65 20 Type III Not found –
12 S41 0 0 80 15 Type III c.(210_294)_(929_1010)del 4–9c
13 S42 0 0 50 25 Type I Not found –
14 S43 0 0 76 19 Type III Not found –
15 S44 0 0 59 25 Type I c.(?_-133)_(*1_?)del All
16 S45 0 0 72 45 Type III Not found –
17 S46 3 0 56 21 Type I Not found –
18 S52 5 3 71 13 Type III Not found –123
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Wrmation.
Quantitative PCR analysis
A qPCR analysis was performed for patients that presented
with deletions in the MLPA analysis (Hoebeeck et al. 2005;
Johansson et al. 2005; Yin et al. 2007). Primers were
designed for intron 4, intron 6, and intron 10 of PROS1,
avoiding concurrent ampliWcation of PROSP. For normali-
zation, we designed primers for genes of which the copy
number is not known to vary, namely GPR15, ZIC4 (both
on chromosome 3) and PRR15 (on chromosome 7). Primers
are described in Table 2. Nine family members with normal
values of PS were evaluated as controls. The qPCR was
performed using SYBR-Green detector on an ABI Prism
7900HT Fast Real Time PCR system (Applied Biosystems,
Foster City, CA, USA). Reaction mixtures contained 1£
SYBR-Green® PCR Master Mix (Applied Biosystems, Fos-
ter City, CA, USA), 200 nM of each primer and 1 ng/l of
template DNA in a total volume of 25 l. Samples were
analyzed in duplicate and a second run was performed to
conWrm the results. Cycling conditions were as follows:
10 min on 95°C, 40 cycles consisting of 94°C for 15 s and
60°C for 1 min. Data were analyzed with the ABI Prism
7900 sequence detection system (version 2.2.2; Applied
Biosystems, Foster City, CA, USA) and quantiWed with the
comparative threshold cycle method using the genes
mentioned above as a reference (de Visser et al. 2008). The
fold diVerence expected for a normal individual with one
copy of the gene per haploid is 1. The expected fold diVer-
ence for an individual with a deletion in one of the chromo-
somes is 0.5 and the fold diVerence for an individual with a
duplication will be 1.5.
Results
MLPA analysis
CNV was detected in six out of eighteen PS deWcient pro-
bands (Table 1). Of these six individuals Wve were classi-
Wed as type I deWcient and one as type III deWcient.
Complete deletion of PROS1 was detected in three pro-
bands with type I deWciency. Two probands appeared to
have a partial deletion involving diVerent parts of the gene;
one from exon 4 through 9 (type III deWciency) and another
from exon 9 through 11 (type I deWciency). In one family
with type I deWciency a duplication of at least exon 4
through 11 was detected. Three out of six probands with a
CNV had other family members available for analysis and
three were isolated probands. In the family members (fam-
ily 2, 4 and 8) the CNVs were shown to co-segregate with
PS deWciency (Fig. 1). A representative example of how a
gene deletion shows up in a MLPA analysis is given in
Fig. 2.
Table 2 Primers for quantitative PCR technique
Gene product GeneID Forward primer Reverse primer
PROS1 intron4 5627 5GTCCCACCAGTTTGGAAGGA 5GCAGGCATCCACTCTGATCTTA
PROS1 intron6 5627 5GGTCCAAAGGCCAATCTGTTAT 5CCCATACCAGCAGACACTACCA
PROS1 intron10 5627 5GCCATGATGAGGATGTGGATT 5CCACAAAGCCATTAGCTTCTGA
GPR15 2838 5CATTGTGACCTGCTACTGTTGCA 5TTTGTTGTGCTTTCCTGATTGC
ZIC4 84107 5CGGTTTCCCTGAGTTCTTTTCA 5GCCAGGATTCCAGTGTGACCTA
PRR15 222171 5CCCAGGTGCTTATCCAAAGG 5TGACTGTAGATGGACGCCAAA
Fig. 1 Family trees of probands that presented with copy number variation in the MLPA analysis showing co-segregation of deletions/duplications
with PS deWciency. Arrows indicate probands (P). Year of birth (b.) is indicated together with sample number123
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As a conWrmation tool, qPCR was performed for PROS1
introns 4, 6 and 10, and three genes elsewhere in the
genome were used for normalization. Nine out of ten indi-
viduals (Wve probands and four family members) who
showed variation in the MLPA analysis were evaluated.
DNA from proband S3, with a putative partial duplication
by MLPA analysis, was not available in suYcient quantities
for further tests.
We performed analyzes using three diVerent control
genes for normalization. When ZIC4 (on chromosome 3)
and PRR15 (on chromosome 7) were used for normaliza-
tion, the qPCR conWrmed all MLPA results. However,
when GPR15 (chromosome 3) was used as reference gene,
one of the families (family 8, samples S33, S34, S36 and
S37) presented with a fold change of 1 suggesting that the
deletion also involved this control gene. GPR15 is located
on chromosome 3 at location 3q11.2-q13.1, approximately
5 Mb upstream (telomeric) from exon 1 of PROS1. Because
the qPCR returned a fold change of 0.5 when ZIC4, which
is far upstream from exon 1 of PROS1, and when PRR15,
which is on chromosome 7, were used for normalization,
we conclude that the deletion in this family involves
PROS1 and GPR15, including at least 20 conWrmed genes
in between.
Discussion
In this study, we evaluated eighteen probands with PS deW-
ciency in whom mutations were not found by exon targeted
sequencing. Ten out of eighteen probands were type I deW-
cient and eight were type III deWcient. Nine of the probands
had family members that could be studied. In six out of
eighteen probands (33%) we discovered deletions or dupli-
cations in PROS1 with the MLPA method. Of these six, one
had type III deWciency (isolated proband) and the others
had type I deWciency (two isolated probands and three pro-
bands with family members).
To conWrm the deletions found by MLPA, we performed
a qPCR analysis using primers that were designed for
selected introns and we chose three genes for normalization
(GPR15 and ZIC4 on chromosome 3 and PRR15 on chro-
mosome 7). Surprisingly, four members from one of the
families possessed a very large deletion that also involved
GPR15, 5 Mb upstream from exon 1 of PROS1. Evidence
that PROS1 deletions might involve nearby genes up to at
Fig. 2 Example of a MLPA electropherogram of a patient with a
PROS1 deletion (top) and a control (bottom). Exons peaks are high-
lighted by bars and indicated by their names. Non-highlighted peaks
correspond to control genes. x-axis represents the fragment size in base
pair. Note that the height of the exon peaks compared to the Xanking
control peaks is lower in the patient in comparison to the control. Tak-
ing exon 6 as an example, the arrows indicate the Xanking control
genes to which exon 6 is compared. For objective comparison we used
the relative peak area, which was calculated by the division of a given
exon peak area by the sum of the peak areas of Xanking control genes.
Variation of more than 35% is considered a deletion (if less) or a dupli-
cation (if more)123
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2005; Yin et al. 2007; Yoo et al. 2009), but deletions larger
than that were not reported. On the basis of the available
data it is not possible to delineate how far the deletion
extends beyond GPR15, but this result illustrates that some
PS deWcient families may have quite large deletions of
chromosome 3. We do not have access to further clinical
information from this family but it is possible that, because
the deleted genes are all in a haploinsuYciency state, no
other inherited diseases are apparent. It may be worthwhile
in the future to evaluate selected PS deWcient patients for
the presence of other inherited disorders.
Although more than 200 mutations have been described in
PS deWcient patients, less than 5% are gross deletions or
duplications [Gandrille et al. 2000; Stenson et al. 2009 at
HGMD (http://www.hgmd.cf.ac.uk/ac. Accessed 12 May
2009)]. Until 2005, only two large deletions were described
in PROS1 (Ploos van Amstel et al. 1989; Schmidel et al.
1991). One of the likely reasons for this is that the detection
technique, i.e. Southern blotting, is laborious and time-con-
suming. Moreover, Southern blots of PROS1 can not be eas-
ily interpreted because of the presence of the PS pseudogene.
Johansson et al. (2005) found large deletions in three out
of eight investigated PS deWcient families (38%, all type I
and mixed type I/III deWciency), who were PROS1 muta-
tion-negative, suggesting that CNVs are an important factor
in PS deWciency. These authors performed a segregation
analysis using a dense set of SNPs and microsatellite mark-
ers and this approach proved to be eYcient in some fami-
lies. In other families the markers were not informative,
showing the limitations of the use of segregation analysis.
Furthermore, PROS1 is not directly targeted and deletions/
duplications of exons that are not covered by the micro-
satellite markers could easily be missed.
Three recent case-reports document two large deletions
and one large duplication in PROS1 (Choung et al. 2008;
Yin et al. 2007; Yoo et al. 2009). In these three studies,
MLPA was used to screen for CNVs, underlining the use-
fulness of this technique for the examination of large gene
rearrangements, even in a single patient. In the present
study, we provided further evidence that gross CNVs are an
important cause of PS deWciency in both families and iso-
lated cases. We found deletions or duplications in 50% of
the type I (5 out of 10), and 12.5% of the type III deWcient
(1 out of 8) point mutation-negative probands, suggesting
that gene deletions are less common in type III families.
This is, of course, not surprising as type III individuals have
(near) normal levels of total PS, which is not easily recon-
ciled with a gene deletion. It is also interesting to note that
the only type III deWcient patient with a CNV was an iso-
lated proband, which does not exclude that it comes from a
family with mixed type I/III deWciency.
The present panel of patients was drawn from a large set
of French PS deWcient individuals. Eighteen probands with
a high probability of having a hereditary PS deWciency
were selected. In 33% of the probands we found a CNV,
showing that deletions/duplications are common in patients
with putative hereditary PS deWciency. However, one
should take care in extrapolating those numbers to consecu-
tive patients with PS deWciency. Together, it seems to be
worthwhile to include MLPA as a screening tool when
investigating the molecular bases of hereditary PS deW-
ciency.
We can only speculate on the reasons why CNVs occur
quite frequently in the PROS1 gene. Out of the Wve dele-
tions and one duplication, three involved the complete
gene, and one of these extends at least 5 Mb to the 5(telo-
meric)-direction. Previous studies have also shown large
deletions of PROS1 involving exon 1 and nearby genes
(Johansson et al. 2005; Yin et al. 2007; Yoo et al. 2009)
which gave rise to the idea that there could be a rearrange-
ment focus somewhere telomeric to the NSUN3 gene (Yoo
et al. 2009), but this claim was never objectively analyzed.
In the remaining cases, exons 4, 9, and 11 where always
involved. Thus, a hotspot for rearrangement might exist
somewhere in these regions of PROS1. Further, the Wrst
case of PS deWciency due to a translocation
[t(3;21)(q11.2;q22)] was recently described (Hurtado et al.
2009), reinforcing the idea that the PROS1 locus may be
prone to structural changes. It has been shown that highly
homologous low copy repeat structures, as well as AT-rich
palindromes and peri-centromeric repeats are located at
breakpoints of rearrangement leading to both homologous
recombination and non-homologous end joining rearrange-
ments mechanisms (Shaw and Lupski 2004).
Despite that this paper and those that precede it now
report that CNVs are quite common in PS deWciency, there
remains a large part of PS deWciency with unknown genetic
causes. There are several possible reasons for this. First, the
MLPA technique that was used did cover most, but still not
all of the exons, so it remains possible that small deletions
that hit these exons are often present in the remaining cases.
The reason that some exons are not covered has to do with
interference by the PS pseudogene in the MLPA reactions
or with diYculty in examining AT rich regions. Secondly,
the promoter region of PROS1 was only recently characterized
and perhaps mutations in this region are quite common.
Mutation analysis in the past has only poorly covered this
region of the gene (de Wolf et al. 2006; Tatewaki et al.
2003). Thirdly, inversions of parts of the gene can not be
ruled out by the MLPA technique as this does not change
the copy numbers of the exons. Finally, recombination
between gene and pseudogene may go unnoticed with the
currently available detection techniques.123
Hum Genet (2009) 126:449–456 455In conclusion, this study conWrms that gross gene abnor-
malities in PROS1 are common in PS deWcient patients and
it appears that MLPA is a useful tool in direct screening for
copy number changes in PROS1. The qPCR conWrmed the
results, which underlines the accuracy of MLPA as a
screening tool.
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